Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT07389161
Recruiting Not applicable

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

NCT07389161 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Skane
Phase
Not applicable
Started
2026-04-28
Last updated
2026-04-29

Condition(s) studied

Mb CrohnUlcerative Colitis (UC)

Investigational drug(s) / intervention(s)

Nordiet

Nordiet: Intervention with a Mediterranean like diet, the so called "Nordiet" during four weeks.

Study summary

The aims of the study are 1. to determine the effect on dysbiosis, permeability and inflammatory activity after administration of a Mediterranean like diet (a Nordic equivalent, "Nordiet"), 2. to investigate life style related factors, such as exercise, psychosexual health and quality of life and their relation to the disease activity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: * IBD, i.e., Mb Crohn or ulcerrative colitis * Moderatively active disease (calprotectin 200-600) Exclusion Criteria: * Proctitis alone * Inactive disease * Severe flare up requiring in-patient care * Planned change of treatment * Antibiotic treatment during the last month * Pregnancy * Inability to understand Swedish * Multimorbidity

Primary outcome measure(s)

  • Microbial composition — Four weeks
    Gut microbiota will be analyzed at start and after four weeks. The health promoting efect of the diet will be estimated with analysis of the total bacterial genome down to species level. The bacterial composition will then be analyzed with regard to presence of beneficial or harmful bacteria. Based on the complexity of the micorbiota it is not possible to state any specific value that should be achieved.

Trial sites (1)

FacilityCityRegionStatus
Skåne University Hospital Malmö Sweden Recruiting

More Region Skane trials in Sweden

Sustainable Hypertension Management in Primary Health Care in Sweden Recruiting
Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy Active, not recruiting
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia Recruiting
The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation. Recruiting
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease Recruiting

Other trials for the same condition

TRIOCOL - The Study of Continued Advanced Medical Therapy or Colectomy in Patients With Ulcerative Colitis Recruiting
Food Limitations In Crohn's Disease and Ulcerative coliTis Enrolling by invitation
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery Starting soon
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Active, not recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07389161 on ClinicalTrials.gov ↗ ← All trials in Sweden